The dynamics of the current COVID-19 pandemic could offer valuable insights for the efforts to mitigate climate change.
In a novel proof of concept study, published on the bioRxiv preprint server, U.S. researchers used attenuated influenza viral particles that express severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) receptor-binding domain to induce neutralizing antibodies in mice – unveiling another viable vaccine candidate for preventing coronavirus disease (COVID-19).
A recent study published in the journal JAMA Network Open reveals that the excess death toll observed during the initial period of coronavirus disease 2019 (COVID-19) pandemic in New York City is comparable to that observed during the peak of the H1N1 influenza pandemic in 1918.
First appearing in late 2019 in Wuhan City, China, the SARS-CoV-2 virus continues to cause sickness and death across the globe.
Mayra Ramirez remembers the nightmares. During six weeks on life support at Northwestern Memorial Hospital in Chicago, Ramirez said, she had terrifying nightmares that she couldn't distinguish from reality.
As the COVID-19 pandemic continues to take thousands of lives every day in different parts of the world, vaccine and antiviral research is continuing, as the only hope of emergence from under its shadow. However, a recent study by researcher Bhavin S Khatri at Imperial College London and published on the preprint server medRxiv* in August 2020 suggests that the pandemic may die out more rapidly than thought, provided the reproduction number is kept low.
Xin Ning, an assistant professor of aerospace engineering, specializes in developing materials for use in space.
A new study published on the preprint server bioRxiv* in August 2020 reports the preliminary results of the US Expanded Access Program (EAP) for CP. The EAP aimed to facilitate access to CP as well as to evaluate the safety of this therapy. However, the current study reports the results of an initial assessment of this agent.
In light of the continuing threat to public health, social functioning, and economic activity posed by the COVID-19 pandemic, scientists are working urgently to bring out a vaccine that is both safe and effective, and capable of mass production. A new paper published on the preprint server bioRxiv* in August 2020 shows that such a vaccine may be produced by using arrays of one severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) protein on a nanoparticle platform.
Now, a novel experimental vaccine that is made from a mild virus genetically-modified to carry an essential gene from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes the coronary disease (COVID-19), has shown promise in preventing pneumonia in mice infected with the virus.
An online COVID-19 symptom tracking tool developed by researchers at Georgetown University Medical Center ensures a person's confidentiality while being able to actively monitor their symptoms.
USC researchers have found the likely order in which COVID-19 symptoms first appear: fever, cough, muscle pain, and then nausea, and/or vomiting, and diarrhea.
Advantech, a global leader of advanced IoT intelligence systems and embedded platforms, is pleased to announce the launch of its Visitor Thermal Screening System, as part of its AI-based infection prevention solutions, to reduce the risk and spread of COVID-19 in high-traffic and heavily populated environments.